[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-jv0ekGMYRpWqFp_CGbyfbYRDbwLRIAZoCHELeqP-9Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":68,"rows":75},"Eurofarma Laboratorios S.A.",[4],63,false,8,53,13592,11,7,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Skin Care",4,{"name":18,"count":19},"Allergic Rhinitis",3,{"name":21,"count":19},"Asthma",{"name":23,"count":24},"Carcinoma",2,{"name":26,"count":24},"Skin Lesions",{"name":28,"count":24},"Overweight",{"name":30,"count":24},"Obesity",{"name":32,"count":24},"Moderate Asthma",[34,39,44,49,53,58,63],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06905210","Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris","2027-02","Experimental drug",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07318350","Study of Formoterol 6 mcg\u002FFluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg\u002F200 mcg in Patients With Asthma (FORASMA)","2028-03","N0783",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06546735","Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO)","2028-04-30","N0728",{"nctId":50,"briefTitle":51,"date":47,"intervention":52},"NCT06608472","Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension","N0877",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07303322","Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)","2028-07","N1087",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06234345","Study of Fluticasone\u002FFormoterol\u002FGlycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","2028-08","Fluticasone 250mcg\u002FFormoterol 12mcg\u002FGlycopyrronium 25mcg",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07529977","Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.","2028-10-30","Minoxidil oral solution",[69,70,71,72,73,74],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[76,114,136,157,179,197,220,238,260,278,300,318,375,401,437,459,495,528,564,589,607,634,652,678,704,722,740,765,792,810,836,854,879,903,921,948,966,991,1009,1027,1050,1073,1091,1114,1132,1150,1175,1193,1211,1236,1254,1280,1298,1316,1340,1358,1384,1402,1420,1447,1465,1483,1506,1524,1547,1565,1591,1609,1627,1650,1668,1694,1712,1730,1748,1766,1788,1806,1824,1850,1868,1886,1911,1929,1954,1978,2005,2023,2041,2064,2082,2108,2131,2149,2174,2192],{"intervention":38,"totalTrials":24,"cells":77},{"EARLY_PHASE1":78,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":110,"NA":112},{"trials":79,"activeCount":80},[],0,{"trials":82,"activeCount":80},[],{"trials":84,"activeCount":80},[],{"trials":86,"activeCount":109,"soonestReadout":37},[87,97],{"nctId":35,"briefTitle":36,"status":88,"phases":89,"primaryCompletion":37,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":96},"NOT_YET_RECRUITING",[72],"2027-03","2026-03",526,[94,95],"Acne Vulgaris","Acne Vulgaris on the Face",[38],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"NCT05118672","Phase 3 Clinical Trial to Evaluate Paracetamol \u002FFexofenadine \u002FPhenylephrine in Flu and Cold Treatment","COMPLETED",[72],"2025-08-26","2025-03-26",567,[106,107],"Cold","Flu Symptom",[38],1,{"trials":111,"activeCount":80},[],{"trials":113,"activeCount":80},[],{"intervention":57,"totalTrials":109,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":132,"NA":134},{"trials":117,"activeCount":80},[],{"trials":119,"activeCount":80},[],{"trials":121,"activeCount":80},[],{"trials":123,"activeCount":109,"soonestReadout":56},[124],{"nctId":54,"briefTitle":55,"status":88,"phases":125,"primaryCompletion":56,"completion":61,"start":126,"enrollment":127,"conditions":128,"interventions":131},[72],"2027-01",372,[129,130],"Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia",[57],{"trials":133,"activeCount":80},[],{"trials":135,"activeCount":80},[],{"intervention":67,"totalTrials":109,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":153,"NA":155},{"trials":139,"activeCount":80},[],{"trials":141,"activeCount":80},[],{"trials":143,"activeCount":80},[],{"trials":145,"activeCount":109,"soonestReadout":66},[146],{"nctId":64,"briefTitle":65,"status":88,"phases":147,"primaryCompletion":66,"completion":66,"start":148,"enrollment":127,"conditions":149,"interventions":152},[72],"2027-01-31",[150,151],"Androgenetic Alopecia","Androgenetic Alopecia (AGA)",[67],{"trials":154,"activeCount":80},[],{"trials":156,"activeCount":80},[],{"intervention":43,"totalTrials":109,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":175,"NA":177},{"trials":160,"activeCount":80},[],{"trials":162,"activeCount":80},[],{"trials":164,"activeCount":80},[],{"trials":166,"activeCount":109,"soonestReadout":42},[167],{"nctId":40,"briefTitle":41,"status":88,"phases":168,"primaryCompletion":42,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":173},[72],"2028-09","2026-10",174,[32],[43,174],"Alenia®",{"trials":176,"activeCount":80},[],{"trials":178,"activeCount":80},[],{"intervention":174,"totalTrials":109,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":193,"NA":195},{"trials":182,"activeCount":80},[],{"trials":184,"activeCount":80},[],{"trials":186,"activeCount":80},[],{"trials":188,"activeCount":109,"soonestReadout":42},[189],{"nctId":40,"briefTitle":41,"status":88,"phases":190,"primaryCompletion":42,"completion":169,"start":170,"enrollment":171,"conditions":191,"interventions":192},[72],[32],[43,174],{"trials":194,"activeCount":80},[],{"trials":196,"activeCount":80},[],{"intervention":48,"totalTrials":109,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":216,"NA":218},{"trials":200,"activeCount":80},[],{"trials":202,"activeCount":80},[],{"trials":204,"activeCount":80},[],{"trials":206,"activeCount":109,"soonestReadout":47},[207],{"nctId":45,"briefTitle":46,"status":88,"phases":208,"primaryCompletion":47,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},[72],"2028-08-30","2026-11-30",816,[213],"Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms",[48,215],"Vesomni®",{"trials":217,"activeCount":80},[],{"trials":219,"activeCount":80},[],{"intervention":215,"totalTrials":109,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":80},[],{"trials":225,"activeCount":80},[],{"trials":227,"activeCount":80},[],{"trials":229,"activeCount":109,"soonestReadout":47},[230],{"nctId":45,"briefTitle":46,"status":88,"phases":231,"primaryCompletion":47,"completion":209,"start":210,"enrollment":211,"conditions":232,"interventions":233},[72],[213],[48,215],{"trials":235,"activeCount":80},[],{"trials":237,"activeCount":80},[],{"intervention":52,"totalTrials":109,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":256,"NA":258},{"trials":241,"activeCount":80},[],{"trials":243,"activeCount":80},[],{"trials":245,"activeCount":80},[],{"trials":247,"activeCount":109,"soonestReadout":47},[248],{"nctId":50,"briefTitle":51,"status":88,"phases":249,"primaryCompletion":47,"completion":250,"start":210,"enrollment":251,"conditions":252,"interventions":254},[72],"2029-10-30",292,[253],"Essential Arterial Hypertension",[52,255],"Benicar HCT ® Tablets 40 mg\u002F25 mg",{"trials":257,"activeCount":80},[],{"trials":259,"activeCount":80},[],{"intervention":255,"totalTrials":109,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":274,"NA":276},{"trials":263,"activeCount":80},[],{"trials":265,"activeCount":80},[],{"trials":267,"activeCount":80},[],{"trials":269,"activeCount":109,"soonestReadout":47},[270],{"nctId":50,"briefTitle":51,"status":88,"phases":271,"primaryCompletion":47,"completion":250,"start":210,"enrollment":251,"conditions":272,"interventions":273},[72],[253],[52,255],{"trials":275,"activeCount":80},[],{"trials":277,"activeCount":80},[],{"intervention":62,"totalTrials":109,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":296,"NA":298},{"trials":281,"activeCount":80},[],{"trials":283,"activeCount":80},[],{"trials":285,"activeCount":80},[],{"trials":287,"activeCount":109,"soonestReadout":61},[288],{"nctId":59,"briefTitle":60,"status":88,"phases":289,"primaryCompletion":61,"completion":61,"start":290,"enrollment":291,"conditions":292,"interventions":294},[72],"2026-09",1252,[293],"Chronic Obstructive Pulmonary Disease",[62,295],"Comparator - Trimbow®",{"trials":297,"activeCount":80},[],{"trials":299,"activeCount":80},[],{"intervention":295,"totalTrials":109,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":314,"NA":316},{"trials":303,"activeCount":80},[],{"trials":305,"activeCount":80},[],{"trials":307,"activeCount":80},[],{"trials":309,"activeCount":109,"soonestReadout":61},[310],{"nctId":59,"briefTitle":60,"status":88,"phases":311,"primaryCompletion":61,"completion":61,"start":290,"enrollment":291,"conditions":312,"interventions":313},[72],[293],[62,295],{"trials":315,"activeCount":80},[],{"trials":317,"activeCount":80},[],{"intervention":319,"totalTrials":16,"cells":320},"Nimotuzumab",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":350,"PHASE4":371,"NA":373},{"trials":322,"activeCount":80},[],{"trials":324,"activeCount":80},[],{"trials":326,"activeCount":80},[327,338],{"nctId":328,"briefTitle":329,"status":100,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},"NCT01145170","Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma",[71],"2014-06","2014-07","2011-03",40,[336],"Diffuse Intrinsic Brainstem Gliomas",[319],{"nctId":339,"briefTitle":340,"status":341,"phases":342,"primaryCompletion":343,"start":344,"enrollment":80,"conditions":345,"interventions":348},"NCT01301612","Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)","WITHDRAWN",[71],"2017-12","2011-01",[23,346,347],"Adenocarcinoma","Uterine Cervix Adenosquamous Carcinoma",[319,349,349],"Cisplatin",{"trials":351,"activeCount":80},[352,361],{"nctId":353,"briefTitle":354,"status":341,"phases":355,"primaryCompletion":356,"completion":357,"start":356,"enrollment":80,"conditions":358,"interventions":360},"NCT01345084","Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab",[72],"2013-11","2017-11",[23,359],"Head and Neck Cancer",[319,349],{"nctId":362,"briefTitle":363,"status":100,"phases":364,"primaryCompletion":356,"completion":356,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT01249352","A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer",[71,72],"2009-01",104,[368,346],"Esophageal Cancer",[319,349,370],"Fluorouracil",{"trials":372,"activeCount":80},[],{"trials":374,"activeCount":80},[],{"intervention":349,"totalTrials":19,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":387,"PHASE4":397,"NA":399},{"trials":378,"activeCount":80},[],{"trials":380,"activeCount":80},[],{"trials":382,"activeCount":80},[383],{"nctId":339,"briefTitle":340,"status":341,"phases":384,"primaryCompletion":343,"start":344,"enrollment":80,"conditions":385,"interventions":386},[71],[23,346,347],[319,349,349],{"trials":388,"activeCount":80},[389,393],{"nctId":353,"briefTitle":354,"status":341,"phases":390,"primaryCompletion":356,"completion":357,"start":356,"enrollment":80,"conditions":391,"interventions":392},[72],[23,359],[319,349],{"nctId":362,"briefTitle":363,"status":100,"phases":394,"primaryCompletion":356,"completion":356,"start":365,"enrollment":366,"conditions":395,"interventions":396},[71,72],[368,346],[319,349,370],{"trials":398,"activeCount":80},[],{"trials":400,"activeCount":80},[],{"intervention":402,"totalTrials":24,"cells":403},"Formoterol\u002FBudesonide",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":433,"NA":435},{"trials":405,"activeCount":80},[],{"trials":407,"activeCount":80},[],{"trials":409,"activeCount":80},[],{"trials":411,"activeCount":80},[412,424],{"nctId":413,"briefTitle":414,"status":100,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT01167010","A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol\u002FBudesonide and Alenia® in Asthma",[72],"2011-08","2012-02","2011-04",552,[21],[402,422,423],"Foraseq","Alenia",{"nctId":425,"briefTitle":426,"status":100,"phases":427,"primaryCompletion":418,"completion":418,"start":428,"enrollment":429,"conditions":430,"interventions":432},"NCT01001364","A Comparative Study Between Foraseq and Formoterol\u002FBudesonide Inhalation Capsules in Patients with Asthma",[72],"2010-02",88,[431],"ASTHMA",[402,422],{"trials":434,"activeCount":80},[],{"trials":436,"activeCount":80},[],{"intervention":422,"totalTrials":24,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":455,"NA":457},{"trials":440,"activeCount":80},[],{"trials":442,"activeCount":80},[],{"trials":444,"activeCount":80},[],{"trials":446,"activeCount":80},[447,451],{"nctId":413,"briefTitle":414,"status":100,"phases":448,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":449,"interventions":450},[72],[21],[402,422,423],{"nctId":425,"briefTitle":426,"status":100,"phases":452,"primaryCompletion":418,"completion":418,"start":428,"enrollment":429,"conditions":453,"interventions":454},[72],[431],[402,422],{"trials":456,"activeCount":80},[],{"trials":458,"activeCount":80},[],{"intervention":460,"totalTrials":24,"cells":461},"Lactase",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":491,"NA":493},{"trials":463,"activeCount":80},[],{"trials":465,"activeCount":80},[],{"trials":467,"activeCount":80},[],{"trials":469,"activeCount":80},[470,481],{"nctId":471,"briefTitle":472,"status":100,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT01145339","A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)",[72],"2011-11","2012-03","2011-07",140,[479],"Hypolactasia",[460],{"nctId":482,"briefTitle":483,"status":100,"phases":484,"primaryCompletion":475,"completion":485,"start":486,"enrollment":477,"conditions":487,"interventions":489},"NCT01145586","A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia",[72],"2012-05","2011-06",[488],"Lactose Intolerance",[490],"Lactase Oral",{"trials":492,"activeCount":80},[],{"trials":494,"activeCount":80},[],{"intervention":496,"totalTrials":24,"cells":497},"Administration of Comparator",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":524,"NA":526},{"trials":499,"activeCount":80},[],{"trials":501,"activeCount":80},[],{"trials":503,"activeCount":80},[],{"trials":505,"activeCount":80},[506,514],{"nctId":507,"briefTitle":508,"status":341,"phases":509,"primaryCompletion":510,"completion":510,"start":91,"enrollment":80,"conditions":511,"interventions":512},"NCT05637710","Parallel, Double-dummy, Superiority Study Levocetirizine\u002FPseudoephedrine x Zina for Allergic Rhinitis in Brazil",[72],"2027-05",[18],[513,496],"Administration of investigation of Eurofarma drug",{"nctId":515,"briefTitle":516,"status":341,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":80,"conditions":520,"interventions":521},"NCT05735431","Non-Inferiority,Combination Formoterol\u002FFluticasonexAlenia®Formoterol\u002FBudesonide for Asthma in Brazil",[72],"2027-11","2026-06",[32],[522,523],"Administration of investigation drug","Administration of comparator",{"trials":525,"activeCount":80},[],{"trials":527,"activeCount":80},[],{"intervention":529,"totalTrials":24,"cells":530},"Tylex",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":560,"NA":562},{"trials":532,"activeCount":80},[],{"trials":534,"activeCount":80},[],{"trials":536,"activeCount":80},[],{"trials":538,"activeCount":80},[539,551],{"nctId":540,"briefTitle":541,"status":100,"phases":542,"primaryCompletion":543,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":549},"NCT04972292","Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction",[72],"2024-05-28","2024-05-30","2023-11-08",288,[548],"Pain",[550,529],"FDC of codeine 30 mg\u002Fdipyrone 500 mg",{"nctId":552,"briefTitle":553,"status":100,"phases":554,"primaryCompletion":543,"completion":555,"start":556,"enrollment":546,"conditions":557,"interventions":558},"NCT05081102","Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction",[72],"2024-09-30","2024-03-27",[548],[559,529],"FDC of oxycodone 5 mg\u002Fibuprofen 400 mg",{"trials":561,"activeCount":80},[],{"trials":563,"activeCount":80},[],{"intervention":565,"totalTrials":109,"cells":566},"Desloratadine , Prednisolone",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":585,"NA":587},{"trials":568,"activeCount":80},[],{"trials":570,"activeCount":80},[],{"trials":572,"activeCount":80},[],{"trials":574,"activeCount":80},[575],{"nctId":576,"briefTitle":577,"status":100,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT05214911","Fixed Dose Combination of Desloratadine \u002F Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children",[72],"2025-03-23","2024-07-08",262,[18],[565,584],"Desloratadine",{"trials":586,"activeCount":80},[],{"trials":588,"activeCount":80},[],{"intervention":584,"totalTrials":109,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":603,"NA":605},{"trials":592,"activeCount":80},[],{"trials":594,"activeCount":80},[],{"trials":596,"activeCount":80},[],{"trials":598,"activeCount":80},[599],{"nctId":576,"briefTitle":577,"status":100,"phases":600,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":601,"interventions":602},[72],[18],[565,584],{"trials":604,"activeCount":80},[],{"trials":606,"activeCount":80},[],{"intervention":608,"totalTrials":109,"cells":609},"Inj. Goserelin (Test) Subcutaneously",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":630,"NA":632},{"trials":611,"activeCount":80},[],{"trials":613,"activeCount":80},[],{"trials":615,"activeCount":80},[],{"trials":617,"activeCount":80},[618],{"nctId":619,"briefTitle":620,"status":100,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT03936218","Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer",[72],"2023-11-30","2024-04-01","2020-09-30",94,[627],"Advanced Prostate Cancer",[608,629],"Inj. Zoladex (Reference) Subcutaneously",{"trials":631,"activeCount":80},[],{"trials":633,"activeCount":80},[],{"intervention":629,"totalTrials":109,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":648,"NA":650},{"trials":637,"activeCount":80},[],{"trials":639,"activeCount":80},[],{"trials":641,"activeCount":80},[],{"trials":643,"activeCount":80},[644],{"nctId":619,"briefTitle":620,"status":100,"phases":645,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":646,"interventions":647},[72],[627],[608,629],{"trials":649,"activeCount":80},[],{"trials":651,"activeCount":80},[],{"intervention":653,"totalTrials":109,"cells":654},"Alenia® 12mcg + 400mcg \u002F Alenia® 6mcg + 200mcg",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":661,"PHASE4":674,"NA":676},{"trials":656,"activeCount":80},[],{"trials":658,"activeCount":80},[],{"trials":660,"activeCount":80},[],{"trials":662,"activeCount":80},[663],{"nctId":664,"briefTitle":665,"status":100,"phases":666,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT04233190","A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment",[72],"2024-10-28","2024-10-30","2023-04-19",472,[672],"Asthma Copd",[653],{"trials":675,"activeCount":80},[],{"trials":677,"activeCount":80},[],{"intervention":679,"totalTrials":109,"cells":680},"Liquaemin",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":700,"NA":702},{"trials":682,"activeCount":80},[],{"trials":684,"activeCount":80},[],{"trials":686,"activeCount":80},[],{"trials":688,"activeCount":80},[689],{"nctId":690,"briefTitle":691,"status":100,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":698},"NCT05148377","UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.",[72],"2008-12-01","2007-08-01",128,[697],"Hemodialysis Complication",[679,699],"Heptar",{"trials":701,"activeCount":80},[],{"trials":703,"activeCount":80},[],{"intervention":699,"totalTrials":109,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":718,"NA":720},{"trials":707,"activeCount":80},[],{"trials":709,"activeCount":80},[],{"trials":711,"activeCount":80},[],{"trials":713,"activeCount":80},[714],{"nctId":690,"briefTitle":691,"status":100,"phases":715,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":716,"interventions":717},[72],[697],[679,699],{"trials":719,"activeCount":80},[],{"trials":721,"activeCount":80},[],{"intervention":423,"totalTrials":109,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":736,"NA":738},{"trials":725,"activeCount":80},[],{"trials":727,"activeCount":80},[],{"trials":729,"activeCount":80},[],{"trials":731,"activeCount":80},[732],{"nctId":413,"briefTitle":414,"status":100,"phases":733,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":734,"interventions":735},[72],[21],[402,422,423],{"trials":737,"activeCount":80},[],{"trials":739,"activeCount":80},[],{"intervention":741,"totalTrials":109,"cells":742},"Glucosamine and chondroitin sulfate combination",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":761,"NA":763},{"trials":744,"activeCount":80},[],{"trials":746,"activeCount":80},[],{"trials":748,"activeCount":80},[],{"trials":750,"activeCount":80},[751],{"nctId":752,"briefTitle":753,"status":100,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT02830919","Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL)",[72],"2019-05-10","2016-12-05",627,[759],"Osteoarthritis of Knee",[741,741],{"trials":762,"activeCount":80},[],{"trials":764,"activeCount":80},[],{"intervention":766,"totalTrials":109,"cells":767},"Heparin Sodium - Eurofarma",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":774,"PHASE4":788,"NA":790},{"trials":769,"activeCount":80},[],{"trials":771,"activeCount":80},[],{"trials":773,"activeCount":80},[],{"trials":775,"activeCount":80},[776],{"nctId":777,"briefTitle":778,"status":779,"phases":780,"primaryCompletion":781,"completion":782,"start":781,"enrollment":783,"conditions":784,"interventions":786},"NCT01352039","A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery","TERMINATED",[72],"2011-10","2012-10",544,[785],"Hip Fracture Surgery",[766,787],"Heparin Sodium - APP Pharmaceuticals",{"trials":789,"activeCount":80},[],{"trials":791,"activeCount":80},[],{"intervention":787,"totalTrials":109,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":806,"NA":808},{"trials":795,"activeCount":80},[],{"trials":797,"activeCount":80},[],{"trials":799,"activeCount":80},[],{"trials":801,"activeCount":80},[802],{"nctId":777,"briefTitle":778,"status":779,"phases":803,"primaryCompletion":781,"completion":782,"start":781,"enrollment":783,"conditions":804,"interventions":805},[72],[785],[766,787],{"trials":807,"activeCount":80},[],{"trials":809,"activeCount":80},[],{"intervention":811,"totalTrials":109,"cells":812},"Dextralgen",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":832,"NA":834},{"trials":814,"activeCount":80},[],{"trials":816,"activeCount":80},[],{"trials":818,"activeCount":80},[],{"trials":820,"activeCount":80},[821],{"nctId":822,"briefTitle":823,"status":100,"phases":824,"primaryCompletion":474,"completion":825,"start":826,"enrollment":827,"conditions":828,"interventions":830},"NCT01147289","Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain",[72],"2012-04","2011-02",280,[829],"Lumbar Sciatic Pain",[811,831],"Meloxicam",{"trials":833,"activeCount":80},[],{"trials":835,"activeCount":80},[],{"intervention":831,"totalTrials":109,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":850,"NA":852},{"trials":839,"activeCount":80},[],{"trials":841,"activeCount":80},[],{"trials":843,"activeCount":80},[],{"trials":845,"activeCount":80},[846],{"nctId":822,"briefTitle":823,"status":100,"phases":847,"primaryCompletion":474,"completion":825,"start":826,"enrollment":827,"conditions":848,"interventions":849},[72],[829],[811,831],{"trials":851,"activeCount":80},[],{"trials":853,"activeCount":80},[],{"intervention":855,"totalTrials":109,"cells":856},"Minoxidil Topical Foam",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":875,"NA":877},{"trials":858,"activeCount":80},[],{"trials":860,"activeCount":80},[],{"trials":862,"activeCount":80},[],{"trials":864,"activeCount":80},[865],{"nctId":866,"briefTitle":867,"status":100,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":874},"NCT04721548","Treatment of Androgenetic Alopecia in Men for 24 Weeks",[72],"2024-03-06","2023-03-02",336,[873],"Alopecia",[855],{"trials":876,"activeCount":80},[],{"trials":878,"activeCount":80},[],{"intervention":880,"totalTrials":109,"cells":881},"Eszopiclone",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":899,"NA":901},{"trials":883,"activeCount":80},[],{"trials":885,"activeCount":80},[],{"trials":887,"activeCount":80},[],{"trials":889,"activeCount":80},[890],{"nctId":891,"briefTitle":892,"status":100,"phases":893,"primaryCompletion":475,"completion":825,"start":333,"enrollment":894,"conditions":895,"interventions":897},"NCT01100164","A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia",[72],263,[896],"INSOMNIA",[880,898],"Zopiclone",{"trials":900,"activeCount":80},[],{"trials":902,"activeCount":80},[],{"intervention":898,"totalTrials":109,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":917,"NA":919},{"trials":906,"activeCount":80},[],{"trials":908,"activeCount":80},[],{"trials":910,"activeCount":80},[],{"trials":912,"activeCount":80},[913],{"nctId":891,"briefTitle":892,"status":100,"phases":914,"primaryCompletion":475,"completion":825,"start":333,"enrollment":894,"conditions":915,"interventions":916},[72],[896],[880,898],{"trials":918,"activeCount":80},[],{"trials":920,"activeCount":80},[],{"intervention":922,"totalTrials":109,"cells":923},"Diurisa®",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":944,"NA":946},{"trials":925,"activeCount":80},[],{"trials":927,"activeCount":80},[],{"trials":929,"activeCount":80},[],{"trials":931,"activeCount":80},[932],{"nctId":933,"briefTitle":934,"status":779,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":942},"NCT01210365","Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema",[72],"2013-03-01","2013-03","2011-01-01",27,[941],"Congestive Heart Failure",[922,943],"Lasix ®",{"trials":945,"activeCount":80},[],{"trials":947,"activeCount":80},[],{"intervention":943,"totalTrials":109,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":962,"NA":964},{"trials":951,"activeCount":80},[],{"trials":953,"activeCount":80},[],{"trials":955,"activeCount":80},[],{"trials":957,"activeCount":80},[958],{"nctId":933,"briefTitle":934,"status":779,"phases":959,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":960,"interventions":961},[72],[941],[922,943],{"trials":963,"activeCount":80},[],{"trials":965,"activeCount":80},[],{"intervention":967,"totalTrials":109,"cells":968},"N0750",{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":975,"PHASE4":987,"NA":989},{"trials":970,"activeCount":80},[],{"trials":972,"activeCount":80},[],{"trials":974,"activeCount":80},[],{"trials":976,"activeCount":80},[977],{"nctId":978,"briefTitle":979,"status":341,"phases":980,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":982,"interventions":984},"NCT06715462","Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy",[72],"2026-04",[983],"Painful Diabetic Peripheral Neuropathy (PDPN)",[967,985,986],"Cymbalta®","Lyrica®",{"trials":988,"activeCount":80},[],{"trials":990,"activeCount":80},[],{"intervention":985,"totalTrials":109,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1005,"NA":1007},{"trials":994,"activeCount":80},[],{"trials":996,"activeCount":80},[],{"trials":998,"activeCount":80},[],{"trials":1000,"activeCount":80},[1001],{"nctId":978,"briefTitle":979,"status":341,"phases":1002,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":1003,"interventions":1004},[72],[983],[967,985,986],{"trials":1006,"activeCount":80},[],{"trials":1008,"activeCount":80},[],{"intervention":986,"totalTrials":109,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":80},[],{"trials":1014,"activeCount":80},[],{"trials":1016,"activeCount":80},[],{"trials":1018,"activeCount":80},[1019],{"nctId":978,"briefTitle":979,"status":341,"phases":1020,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":1021,"interventions":1022},[72],[983],[967,985,986],{"trials":1024,"activeCount":80},[],{"trials":1026,"activeCount":80},[],{"intervention":1028,"totalTrials":109,"cells":1029},"Filgrastim",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1046,"NA":1048},{"trials":1031,"activeCount":80},[],{"trials":1033,"activeCount":80},[],{"trials":1035,"activeCount":80},[],{"trials":1037,"activeCount":80},[1038],{"nctId":1039,"briefTitle":1040,"status":100,"phases":1041,"primaryCompletion":418,"completion":782,"start":333,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT01079676","A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer",[72],220,[1044],"Neutropenia in Breast Cancer",[1028,1028],{"trials":1047,"activeCount":80},[],{"trials":1049,"activeCount":80},[],{"intervention":1051,"totalTrials":109,"cells":1052},"Norfloxacin",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1069,"NA":1071},{"trials":1054,"activeCount":80},[],{"trials":1056,"activeCount":80},[],{"trials":1058,"activeCount":80},[],{"trials":1060,"activeCount":80},[1061],{"nctId":1062,"briefTitle":1063,"status":341,"phases":1064,"primaryCompletion":782,"start":782,"enrollment":80,"conditions":1065,"interventions":1067},"NCT01527019","Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)",[72],[1066],"Cystitis",[1051,1068,1068],"Cephalosporins",{"trials":1070,"activeCount":80},[],{"trials":1072,"activeCount":80},[],{"intervention":1068,"totalTrials":109,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":80},[],{"trials":1078,"activeCount":80},[],{"trials":1080,"activeCount":80},[],{"trials":1082,"activeCount":80},[1083],{"nctId":1062,"briefTitle":1063,"status":341,"phases":1084,"primaryCompletion":782,"start":782,"enrollment":80,"conditions":1085,"interventions":1086},[72],[1066],[1051,1068,1068],{"trials":1088,"activeCount":80},[],{"trials":1090,"activeCount":80},[],{"intervention":1092,"totalTrials":109,"cells":1093},"ADF1 Group Eurofarma drug association of Sibutramine IR 15mg \u002F Topiramate XR 75mg",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1110,"NA":1112},{"trials":1095,"activeCount":80},[],{"trials":1097,"activeCount":80},[],{"trials":1099,"activeCount":80},[],{"trials":1101,"activeCount":80},[1102],{"nctId":1103,"briefTitle":1104,"status":341,"phases":1105,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":1106,"interventions":1107},"NCT05209984","A Phase 3, Double-blind\u002FDouble-dummy, Safety\u002FEfficacy\u002FSuperiority of Sibutramine\u002FTopiramate XR in Adults With Overweight",[72],[28,30],[1092,1108,1109],"ADF2 Group Eurofarma drug association of Sibutramine IR 15mg \u002F Topiramate XR 100mg","SIB Group Sibus (Sibutramine) 15mg",{"trials":1111,"activeCount":80},[],{"trials":1113,"activeCount":80},[],{"intervention":1108,"totalTrials":109,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1128,"NA":1130},{"trials":1117,"activeCount":80},[],{"trials":1119,"activeCount":80},[],{"trials":1121,"activeCount":80},[],{"trials":1123,"activeCount":80},[1124],{"nctId":1103,"briefTitle":1104,"status":341,"phases":1125,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":1126,"interventions":1127},[72],[28,30],[1092,1108,1109],{"trials":1129,"activeCount":80},[],{"trials":1131,"activeCount":80},[],{"intervention":1109,"totalTrials":109,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1146,"NA":1148},{"trials":1135,"activeCount":80},[],{"trials":1137,"activeCount":80},[],{"trials":1139,"activeCount":80},[],{"trials":1141,"activeCount":80},[1142],{"nctId":1103,"briefTitle":1104,"status":341,"phases":1143,"primaryCompletion":42,"completion":42,"start":981,"enrollment":80,"conditions":1144,"interventions":1145},[72],[28,30],[1092,1108,1109],{"trials":1147,"activeCount":80},[],{"trials":1149,"activeCount":80},[],{"intervention":1151,"totalTrials":109,"cells":1152},"meloxicam\u002Fcyclobenzaprine hydrochloride",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1171,"NA":1173},{"trials":1154,"activeCount":80},[],{"trials":1156,"activeCount":80},[],{"trials":1158,"activeCount":80},[],{"trials":1160,"activeCount":80},[1161],{"nctId":1162,"briefTitle":1163,"status":341,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":1165,"enrollment":80,"conditions":1166,"interventions":1168},"NCT01587508","Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago",[72],"2013-05",[1167],"Acute Lumbago",[1151,1169,1170],"meloxicam - Movatec®","cyclobenzaprine - Miosan®",{"trials":1172,"activeCount":80},[],{"trials":1174,"activeCount":80},[],{"intervention":1169,"totalTrials":109,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":80},[],{"trials":1180,"activeCount":80},[],{"trials":1182,"activeCount":80},[],{"trials":1184,"activeCount":80},[1185],{"nctId":1162,"briefTitle":1163,"status":341,"phases":1186,"primaryCompletion":1165,"completion":1165,"start":1165,"enrollment":80,"conditions":1187,"interventions":1188},[72],[1167],[1151,1169,1170],{"trials":1190,"activeCount":80},[],{"trials":1192,"activeCount":80},[],{"intervention":1170,"totalTrials":109,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":80},[],{"trials":1198,"activeCount":80},[],{"trials":1200,"activeCount":80},[],{"trials":1202,"activeCount":80},[1203],{"nctId":1162,"briefTitle":1163,"status":341,"phases":1204,"primaryCompletion":1165,"completion":1165,"start":1165,"enrollment":80,"conditions":1205,"interventions":1206},[72],[1167],[1151,1169,1170],{"trials":1208,"activeCount":80},[],{"trials":1210,"activeCount":80},[],{"intervention":1212,"totalTrials":109,"cells":1213},"Chlorthalidone 25 mg + amiloride hydrochloride 5 mg",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1232,"NA":1234},{"trials":1215,"activeCount":80},[],{"trials":1217,"activeCount":80},[],{"trials":1219,"activeCount":80},[],{"trials":1221,"activeCount":80},[1222],{"nctId":1223,"briefTitle":1224,"status":100,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":416,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT01191450","Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension",[72],"2013-08",246,[1229],"Arterial Hypertension",[1212,1231],"Higroton® Laboratório Novartis",{"trials":1233,"activeCount":80},[],{"trials":1235,"activeCount":80},[],{"intervention":1231,"totalTrials":109,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1250,"NA":1252},{"trials":1239,"activeCount":80},[],{"trials":1241,"activeCount":80},[],{"trials":1243,"activeCount":80},[],{"trials":1245,"activeCount":80},[1246],{"nctId":1223,"briefTitle":1224,"status":100,"phases":1247,"primaryCompletion":1226,"completion":1226,"start":416,"enrollment":1227,"conditions":1248,"interventions":1249},[72],[1229],[1212,1231],{"trials":1251,"activeCount":80},[],{"trials":1253,"activeCount":80},[],{"intervention":1255,"totalTrials":109,"cells":1256},"Goserelin acetate 3.6 mg",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1263,"PHASE4":1276,"NA":1278},{"trials":1258,"activeCount":80},[],{"trials":1260,"activeCount":80},[],{"trials":1262,"activeCount":80},[],{"trials":1264,"activeCount":80},[1265],{"nctId":1266,"briefTitle":1267,"status":779,"phases":1268,"primaryCompletion":555,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1274},"NCT03936933","Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer",[72],"2025-01-30","2020-10-30",6,[1273],"Breast Cancer",[1255,1275],"ZOLADEX® 3.6mg",{"trials":1277,"activeCount":80},[],{"trials":1279,"activeCount":80},[],{"intervention":1275,"totalTrials":109,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":80},[],{"trials":1285,"activeCount":80},[],{"trials":1287,"activeCount":80},[],{"trials":1289,"activeCount":80},[1290],{"nctId":1266,"briefTitle":1267,"status":779,"phases":1291,"primaryCompletion":555,"completion":1269,"start":1270,"enrollment":1271,"conditions":1292,"interventions":1293},[72],[1273],[1255,1275],{"trials":1295,"activeCount":80},[],{"trials":1297,"activeCount":80},[],{"intervention":513,"totalTrials":109,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":80},[],{"trials":1303,"activeCount":80},[],{"trials":1305,"activeCount":80},[],{"trials":1307,"activeCount":80},[1308],{"nctId":507,"briefTitle":508,"status":341,"phases":1309,"primaryCompletion":510,"completion":510,"start":91,"enrollment":80,"conditions":1310,"interventions":1311},[72],[18],[513,496],{"trials":1313,"activeCount":80},[],{"trials":1315,"activeCount":80},[],{"intervention":1317,"totalTrials":109,"cells":1318},"Eurofarma's pegfilgrastim",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1336,"NA":1338},{"trials":1320,"activeCount":80},[],{"trials":1322,"activeCount":80},[],{"trials":1324,"activeCount":80},[],{"trials":1326,"activeCount":80},[1327],{"nctId":1328,"briefTitle":1329,"status":341,"phases":1330,"primaryCompletion":1331,"completion":1331,"start":1332,"enrollment":80,"conditions":1333,"interventions":1334},"NCT02768714","Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy",[72],"2019-10","2018-01",[1273],[1317,1335],"Neulastim",{"trials":1337,"activeCount":80},[],{"trials":1339,"activeCount":80},[],{"intervention":1335,"totalTrials":109,"cells":1341},{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1348,"PHASE4":1354,"NA":1356},{"trials":1343,"activeCount":80},[],{"trials":1345,"activeCount":80},[],{"trials":1347,"activeCount":80},[],{"trials":1349,"activeCount":80},[1350],{"nctId":1328,"briefTitle":1329,"status":341,"phases":1351,"primaryCompletion":1331,"completion":1331,"start":1332,"enrollment":80,"conditions":1352,"interventions":1353},[72],[1273],[1317,1335],{"trials":1355,"activeCount":80},[],{"trials":1357,"activeCount":80},[],{"intervention":1359,"totalTrials":109,"cells":1360},"glucosamine sulphate 1500mg and meloxicam 15mg",{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1380,"NA":1382},{"trials":1362,"activeCount":80},[],{"trials":1364,"activeCount":80},[],{"trials":1366,"activeCount":80},[],{"trials":1368,"activeCount":80},[1369],{"nctId":1370,"briefTitle":1371,"status":341,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":80,"conditions":1375,"interventions":1377},"NCT03936192","A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study",[72],"2021-02","2019-01",[1376],"Knee Osteoarthritis",[1359,1378,1379],"Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg","Placebos",{"trials":1381,"activeCount":80},[],{"trials":1383,"activeCount":80},[],{"intervention":1378,"totalTrials":109,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":80},[],{"trials":1389,"activeCount":80},[],{"trials":1391,"activeCount":80},[],{"trials":1393,"activeCount":80},[1394],{"nctId":1370,"briefTitle":1371,"status":341,"phases":1395,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":80,"conditions":1396,"interventions":1397},[72],[1376],[1359,1378,1379],{"trials":1399,"activeCount":80},[],{"trials":1401,"activeCount":80},[],{"intervention":1379,"totalTrials":109,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":80},[],{"trials":1407,"activeCount":80},[],{"trials":1409,"activeCount":80},[],{"trials":1411,"activeCount":80},[1412],{"nctId":1370,"briefTitle":1371,"status":341,"phases":1413,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":80,"conditions":1414,"interventions":1415},[72],[1376],[1359,1378,1379],{"trials":1417,"activeCount":80},[],{"trials":1419,"activeCount":80},[],{"intervention":1421,"totalTrials":109,"cells":1422},"Rizatriptan 10 mg + Naproxen 550mg",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1443,"NA":1445},{"trials":1424,"activeCount":80},[],{"trials":1426,"activeCount":80},[],{"trials":1428,"activeCount":80},[],{"trials":1430,"activeCount":80},[1431],{"nctId":1432,"briefTitle":1433,"status":100,"phases":1434,"primaryCompletion":668,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1440},"NCT04384367","Efficacy and Safety of Rizatriptan-Naproxen (10\u002F550 Mg) in the Acute Treatment of Migraine",[72],"2024-11-30","2022-12-30",2068,[1439],"Migraine",[1421,1441,1442],"Maxalt 10Mg","Flanax 550mg",{"trials":1444,"activeCount":80},[],{"trials":1446,"activeCount":80},[],{"intervention":1441,"totalTrials":109,"cells":1448},{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1461,"NA":1463},{"trials":1450,"activeCount":80},[],{"trials":1452,"activeCount":80},[],{"trials":1454,"activeCount":80},[],{"trials":1456,"activeCount":80},[1457],{"nctId":1432,"briefTitle":1433,"status":100,"phases":1458,"primaryCompletion":668,"completion":1435,"start":1436,"enrollment":1437,"conditions":1459,"interventions":1460},[72],[1439],[1421,1441,1442],{"trials":1462,"activeCount":80},[],{"trials":1464,"activeCount":80},[],{"intervention":1442,"totalTrials":109,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":80},[],{"trials":1470,"activeCount":80},[],{"trials":1472,"activeCount":80},[],{"trials":1474,"activeCount":80},[1475],{"nctId":1432,"briefTitle":1433,"status":100,"phases":1476,"primaryCompletion":668,"completion":1435,"start":1436,"enrollment":1437,"conditions":1477,"interventions":1478},[72],[1439],[1421,1441,1442],{"trials":1480,"activeCount":80},[],{"trials":1482,"activeCount":80},[],{"intervention":1484,"totalTrials":109,"cells":1485},"Salmeterol\u002FFluticasone",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1502,"NA":1504},{"trials":1487,"activeCount":80},[],{"trials":1489,"activeCount":80},[],{"trials":1491,"activeCount":80},[],{"trials":1493,"activeCount":80},[1494],{"nctId":1495,"briefTitle":1496,"status":100,"phases":1497,"completion":485,"start":416,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT01202097","A Non- Inferiority Comparative Study Between Seretide® and Salmeterol\u002FFluticasone Eurofarma in Patients with Asthma",[72],334,[21],[1484,1501],"Seretide",{"trials":1503,"activeCount":80},[],{"trials":1505,"activeCount":80},[],{"intervention":1501,"totalTrials":109,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1520,"NA":1522},{"trials":1509,"activeCount":80},[],{"trials":1511,"activeCount":80},[],{"trials":1513,"activeCount":80},[],{"trials":1515,"activeCount":80},[1516],{"nctId":1495,"briefTitle":1496,"status":100,"phases":1517,"completion":485,"start":416,"enrollment":1498,"conditions":1518,"interventions":1519},[72],[21],[1484,1501],{"trials":1521,"activeCount":80},[],{"trials":1523,"activeCount":80},[],{"intervention":1525,"totalTrials":109,"cells":1526},"Pantoprazole + Domperidone",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1543,"NA":1545},{"trials":1528,"activeCount":80},[],{"trials":1530,"activeCount":80},[],{"trials":1532,"activeCount":80},[],{"trials":1534,"activeCount":80},[1535],{"nctId":1536,"briefTitle":1537,"status":341,"phases":1538,"start":1226,"enrollment":80,"conditions":1539,"interventions":1541},"NCT01710462","Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease",[72],[1540],"Gastroesophageal Reflux Disease",[1525,1542],"Pantozol®",{"trials":1544,"activeCount":80},[],{"trials":1546,"activeCount":80},[],{"intervention":1542,"totalTrials":109,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1561,"NA":1563},{"trials":1550,"activeCount":80},[],{"trials":1552,"activeCount":80},[],{"trials":1554,"activeCount":80},[],{"trials":1556,"activeCount":80},[1557],{"nctId":1536,"briefTitle":1537,"status":341,"phases":1558,"start":1226,"enrollment":80,"conditions":1559,"interventions":1560},[72],[1540],[1525,1542],{"trials":1562,"activeCount":80},[],{"trials":1564,"activeCount":80},[],{"intervention":1566,"totalTrials":109,"cells":1567},"Formoterol\u002FFluticasone",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1587,"NA":1589},{"trials":1569,"activeCount":80},[],{"trials":1571,"activeCount":80},[],{"trials":1573,"activeCount":80},[],{"trials":1575,"activeCount":80},[1576],{"nctId":1577,"briefTitle":1578,"status":100,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1584},"NCT01202084","A Study Comparative of Formoterol\u002FFluticasone Foraseq® and Fluticasone in Asthma Patients",[72],"2012-11","2012-01",222,[21],[1566,1585,1586],"Foraseq®","Fluticasone",{"trials":1588,"activeCount":80},[],{"trials":1590,"activeCount":80},[],{"intervention":1585,"totalTrials":109,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":80},[],{"trials":1596,"activeCount":80},[],{"trials":1598,"activeCount":80},[],{"trials":1600,"activeCount":80},[1601],{"nctId":1577,"briefTitle":1578,"status":100,"phases":1602,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1603,"interventions":1604},[72],[21],[1566,1585,1586],{"trials":1606,"activeCount":80},[],{"trials":1608,"activeCount":80},[],{"intervention":1586,"totalTrials":109,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":80},[],{"trials":1614,"activeCount":80},[],{"trials":1616,"activeCount":80},[],{"trials":1618,"activeCount":80},[1619],{"nctId":1577,"briefTitle":1578,"status":100,"phases":1620,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":1582,"conditions":1621,"interventions":1622},[72],[21],[1566,1585,1586],{"trials":1624,"activeCount":80},[],{"trials":1626,"activeCount":80},[],{"intervention":1628,"totalTrials":109,"cells":1629},"Noex",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1646,"NA":1648},{"trials":1631,"activeCount":80},[],{"trials":1633,"activeCount":80},[],{"trials":1635,"activeCount":80},[],{"trials":1637,"activeCount":80},[1638],{"nctId":1639,"briefTitle":1640,"status":100,"phases":1641,"primaryCompletion":428,"completion":1642,"start":428,"enrollment":827,"conditions":1643,"interventions":1644},"NCT01022047","Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis",[72],"2010-12",[18],[1628,1645],"Budecort Aqua",{"trials":1647,"activeCount":80},[],{"trials":1649,"activeCount":80},[],{"intervention":1645,"totalTrials":109,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":80},[],{"trials":1655,"activeCount":80},[],{"trials":1657,"activeCount":80},[],{"trials":1659,"activeCount":80},[1660],{"nctId":1639,"briefTitle":1640,"status":100,"phases":1661,"primaryCompletion":428,"completion":1642,"start":428,"enrollment":827,"conditions":1662,"interventions":1663},[72],[18],[1628,1645],{"trials":1665,"activeCount":80},[],{"trials":1667,"activeCount":80},[],{"intervention":1669,"totalTrials":109,"cells":1670},"Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione",{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1690,"NA":1692},{"trials":1672,"activeCount":80},[],{"trials":1674,"activeCount":80},[],{"trials":1676,"activeCount":80},[],{"trials":1678,"activeCount":80},[1679],{"nctId":1680,"briefTitle":1681,"status":341,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":290,"enrollment":80,"conditions":1684,"interventions":1686},"NCT07057479","Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin",[72],"2028-02",[1685],"Type 2 Diabetes Mellitus (T2DM)",[1669,1687,1688,1689],"Control Group 1 Intervention - SGLT2 inhibitor monotherapy","Control Group 2 Intervention - Thiazolidinedione monotherapy","Background Therapy (All Groups) - Metformin",{"trials":1691,"activeCount":80},[],{"trials":1693,"activeCount":80},[],{"intervention":1687,"totalTrials":109,"cells":1695},{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1708,"NA":1710},{"trials":1697,"activeCount":80},[],{"trials":1699,"activeCount":80},[],{"trials":1701,"activeCount":80},[],{"trials":1703,"activeCount":80},[1704],{"nctId":1680,"briefTitle":1681,"status":341,"phases":1705,"primaryCompletion":1683,"completion":1683,"start":290,"enrollment":80,"conditions":1706,"interventions":1707},[72],[1685],[1669,1687,1688,1689],{"trials":1709,"activeCount":80},[],{"trials":1711,"activeCount":80},[],{"intervention":1688,"totalTrials":109,"cells":1713},{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1726,"NA":1728},{"trials":1715,"activeCount":80},[],{"trials":1717,"activeCount":80},[],{"trials":1719,"activeCount":80},[],{"trials":1721,"activeCount":80},[1722],{"nctId":1680,"briefTitle":1681,"status":341,"phases":1723,"primaryCompletion":1683,"completion":1683,"start":290,"enrollment":80,"conditions":1724,"interventions":1725},[72],[1685],[1669,1687,1688,1689],{"trials":1727,"activeCount":80},[],{"trials":1729,"activeCount":80},[],{"intervention":1689,"totalTrials":109,"cells":1731},{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1736,"PHASE3":1738,"PHASE4":1744,"NA":1746},{"trials":1733,"activeCount":80},[],{"trials":1735,"activeCount":80},[],{"trials":1737,"activeCount":80},[],{"trials":1739,"activeCount":80},[1740],{"nctId":1680,"briefTitle":1681,"status":341,"phases":1741,"primaryCompletion":1683,"completion":1683,"start":290,"enrollment":80,"conditions":1742,"interventions":1743},[72],[1685],[1669,1687,1688,1689],{"trials":1745,"activeCount":80},[],{"trials":1747,"activeCount":80},[],{"intervention":522,"totalTrials":109,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1762,"NA":1764},{"trials":1751,"activeCount":80},[],{"trials":1753,"activeCount":80},[],{"trials":1755,"activeCount":80},[],{"trials":1757,"activeCount":80},[1758],{"nctId":515,"briefTitle":516,"status":341,"phases":1759,"primaryCompletion":518,"completion":518,"start":519,"enrollment":80,"conditions":1760,"interventions":1761},[72],[32],[522,523],{"trials":1763,"activeCount":80},[],{"trials":1765,"activeCount":80},[],{"intervention":1767,"totalTrials":109,"cells":1768},"Nexium®",{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1773,"PHASE3":1775,"PHASE4":1784,"NA":1786},{"trials":1770,"activeCount":80},[],{"trials":1772,"activeCount":80},[],{"trials":1774,"activeCount":80},[],{"trials":1776,"activeCount":80},[1777],{"nctId":1778,"briefTitle":1779,"status":341,"phases":1780,"enrollment":80,"conditions":1781,"interventions":1782},"NCT01471925","Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC",[72],[1540],[1767,1783],"Esomeprazol",{"trials":1785,"activeCount":80},[],{"trials":1787,"activeCount":80},[],{"intervention":1783,"totalTrials":109,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1802,"NA":1804},{"trials":1791,"activeCount":80},[],{"trials":1793,"activeCount":80},[],{"trials":1795,"activeCount":80},[],{"trials":1797,"activeCount":80},[1798],{"nctId":1778,"briefTitle":1779,"status":341,"phases":1799,"enrollment":80,"conditions":1800,"interventions":1801},[72],[1540],[1767,1783],{"trials":1803,"activeCount":80},[],{"trials":1805,"activeCount":80},[],{"intervention":370,"totalTrials":109,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1820,"NA":1822},{"trials":1809,"activeCount":80},[],{"trials":1811,"activeCount":80},[],{"trials":1813,"activeCount":80},[],{"trials":1815,"activeCount":80},[1816],{"nctId":362,"briefTitle":363,"status":100,"phases":1817,"primaryCompletion":356,"completion":356,"start":365,"enrollment":366,"conditions":1818,"interventions":1819},[71,72],[368,346],[319,349,370],{"trials":1821,"activeCount":80},[],{"trials":1823,"activeCount":80},[],{"intervention":1825,"totalTrials":109,"cells":1826},"N0892",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1846,"NA":1848},{"trials":1828,"activeCount":80},[],{"trials":1830,"activeCount":80},[],{"trials":1832,"activeCount":80},[],{"trials":1834,"activeCount":80},[1835],{"nctId":1836,"briefTitle":1837,"status":341,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":210,"enrollment":80,"conditions":1841,"interventions":1843},"NCT06560333","iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)",[72],"2027-04-30","2029-02-28",[1842],"Diabetes Mellitus, Type 2",[1825,1844,1845],"Januvia® + Glifage XR® + Placebo","Forxiga® + Glifage XR® + Placebo",{"trials":1847,"activeCount":80},[],{"trials":1849,"activeCount":80},[],{"intervention":1844,"totalTrials":109,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":80},[],{"trials":1855,"activeCount":80},[],{"trials":1857,"activeCount":80},[],{"trials":1859,"activeCount":80},[1860],{"nctId":1836,"briefTitle":1837,"status":341,"phases":1861,"primaryCompletion":1839,"completion":1840,"start":210,"enrollment":80,"conditions":1862,"interventions":1863},[72],[1842],[1825,1844,1845],{"trials":1865,"activeCount":80},[],{"trials":1867,"activeCount":80},[],{"intervention":1845,"totalTrials":109,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":80},[],{"trials":1873,"activeCount":80},[],{"trials":1875,"activeCount":80},[],{"trials":1877,"activeCount":80},[1878],{"nctId":1836,"briefTitle":1837,"status":341,"phases":1879,"primaryCompletion":1839,"completion":1840,"start":210,"enrollment":80,"conditions":1880,"interventions":1881},[72],[1842],[1825,1844,1845],{"trials":1883,"activeCount":80},[],{"trials":1885,"activeCount":80},[],{"intervention":1887,"totalTrials":109,"cells":1888},"Glucosamine sulphate and chondroitin sulphate association",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1907,"NA":1909},{"trials":1890,"activeCount":80},[],{"trials":1892,"activeCount":80},[],{"trials":1894,"activeCount":80},[],{"trials":1896,"activeCount":80},[1897],{"nctId":1898,"briefTitle":1899,"status":100,"phases":1900,"primaryCompletion":826,"completion":486,"start":1901,"enrollment":1902,"conditions":1903,"interventions":1905},"NCT00955552","Efficacy and Safety Study of Glucosamine\u002FChondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee",[72],"2010-08",100,[1904],"Osteoarthritis of the Knee",[1887,1906],"Cosamin DS®",{"trials":1908,"activeCount":80},[],{"trials":1910,"activeCount":80},[],{"intervention":1906,"totalTrials":109,"cells":1912},{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1925,"NA":1927},{"trials":1914,"activeCount":80},[],{"trials":1916,"activeCount":80},[],{"trials":1918,"activeCount":80},[],{"trials":1920,"activeCount":80},[1921],{"nctId":1898,"briefTitle":1899,"status":100,"phases":1922,"primaryCompletion":826,"completion":486,"start":1901,"enrollment":1902,"conditions":1923,"interventions":1924},[72],[1904],[1887,1906],{"trials":1926,"activeCount":80},[],{"trials":1928,"activeCount":80},[],{"intervention":1930,"totalTrials":109,"cells":1931},"Mometasone furoate",{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1938,"PHASE4":1950,"NA":1952},{"trials":1933,"activeCount":80},[],{"trials":1935,"activeCount":80},[],{"trials":1937,"activeCount":80},[],{"trials":1939,"activeCount":80},[1940],{"nctId":1941,"briefTitle":1942,"status":100,"phases":1943,"primaryCompletion":1944,"completion":937,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1949},"NCT01372865","A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)",[72],"2013-02","2012-06",364,[1948],"Mild to Moderate Persistent Allergic Rhinitis",[1930,1930],{"trials":1951,"activeCount":80},[],{"trials":1953,"activeCount":80},[],{"intervention":1955,"totalTrials":109,"cells":1956},"barrier methods",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1974,"NA":1976},{"trials":1958,"activeCount":80},[],{"trials":1960,"activeCount":80},[],{"trials":1962,"activeCount":80},[],{"trials":1964,"activeCount":80},[1965],{"nctId":1966,"briefTitle":1967,"status":341,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":80,"conditions":1971,"interventions":1973},"NCT01557023","Clinical Trial With Combination of Dienogest\u002FEthytnilestradiol and Drosperidona\u002FEthyniestradiol",[72],"2014-12-01","2013-07-01",[1972],"Metrorrhagia",[1955,1955],{"trials":1975,"activeCount":80},[],{"trials":1977,"activeCount":80},[],{"intervention":1979,"totalTrials":109,"cells":1980},"FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1987,"PHASE4":2001,"NA":2003},{"trials":1982,"activeCount":80},[],{"trials":1984,"activeCount":80},[],{"trials":1986,"activeCount":80},[],{"trials":1988,"activeCount":80},[1989],{"nctId":1990,"briefTitle":1991,"status":341,"phases":1992,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":80,"conditions":1996,"interventions":1998},"NCT05683574","Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil",[72],"2027-10-30","2028-02-28","2026-05-30",[1997],"Third Molar Extraction",[1979,1999,2000],"etoricoxib 90 mg (Arcoxia®) +FDC placebo","cyclobenzaprine hydrochloride + etoricoxib placebo",{"trials":2002,"activeCount":80},[],{"trials":2004,"activeCount":80},[],{"intervention":1999,"totalTrials":109,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2019,"NA":2021},{"trials":2008,"activeCount":80},[],{"trials":2010,"activeCount":80},[],{"trials":2012,"activeCount":80},[],{"trials":2014,"activeCount":80},[2015],{"nctId":1990,"briefTitle":1991,"status":341,"phases":2016,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":80,"conditions":2017,"interventions":2018},[72],[1997],[1979,1999,2000],{"trials":2020,"activeCount":80},[],{"trials":2022,"activeCount":80},[],{"intervention":2000,"totalTrials":109,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2037,"NA":2039},{"trials":2026,"activeCount":80},[],{"trials":2028,"activeCount":80},[],{"trials":2030,"activeCount":80},[],{"trials":2032,"activeCount":80},[2033],{"nctId":1990,"briefTitle":1991,"status":341,"phases":2034,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":80,"conditions":2035,"interventions":2036},[72],[1997],[1979,1999,2000],{"trials":2038,"activeCount":80},[],{"trials":2040,"activeCount":80},[],{"intervention":2042,"totalTrials":109,"cells":2043},"Budesonid 50mcg",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2060,"NA":2062},{"trials":2045,"activeCount":80},[],{"trials":2047,"activeCount":80},[],{"trials":2049,"activeCount":80},[],{"trials":2051,"activeCount":80},[2052],{"nctId":2053,"briefTitle":2054,"status":341,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":2056,"enrollment":80,"conditions":2057,"interventions":2059},"NCT02988778","Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis",[72],"2019-10-08",[2058],"Rhinitis, Allergic, Perennial",[2042,2042],{"trials":2061,"activeCount":80},[],{"trials":2063,"activeCount":80},[],{"intervention":550,"totalTrials":109,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2072,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":80},[],{"trials":2069,"activeCount":80},[],{"trials":2071,"activeCount":80},[],{"trials":2073,"activeCount":80},[2074],{"nctId":540,"briefTitle":541,"status":100,"phases":2075,"primaryCompletion":543,"completion":544,"start":545,"enrollment":546,"conditions":2076,"interventions":2077},[72],[548],[550,529],{"trials":2079,"activeCount":80},[],{"trials":2081,"activeCount":80},[],{"intervention":2083,"totalTrials":109,"cells":2084},"Enoxaparin",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2104,"NA":2106},{"trials":2086,"activeCount":80},[],{"trials":2088,"activeCount":80},[],{"trials":2090,"activeCount":80},[],{"trials":2092,"activeCount":80},[2093],{"nctId":2094,"briefTitle":2095,"status":779,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2103},"NCT01356992","Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation",[72],"2013-07","2012-07",62,[2101,2102],"Non ST Segment Elevation Myocardial Infarction","Unstable Angina",[2083],{"trials":2105,"activeCount":80},[],{"trials":2107,"activeCount":80},[],{"intervention":2109,"totalTrials":109,"cells":2110},"Budesonide",{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2117,"PHASE4":2127,"NA":2129},{"trials":2112,"activeCount":80},[],{"trials":2114,"activeCount":80},[],{"trials":2116,"activeCount":80},[],{"trials":2118,"activeCount":80},[2119],{"nctId":2120,"briefTitle":2121,"status":341,"phases":2122,"primaryCompletion":2123,"completion":2123,"start":2124,"enrollment":80,"conditions":2125,"interventions":2126},"NCT02972866","Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis",[72],"2019-11","2016-06",[2058],[2109],{"trials":2128,"activeCount":80},[],{"trials":2130,"activeCount":80},[],{"intervention":559,"totalTrials":109,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2145,"NA":2147},{"trials":2134,"activeCount":80},[],{"trials":2136,"activeCount":80},[],{"trials":2138,"activeCount":80},[],{"trials":2140,"activeCount":80},[2141],{"nctId":552,"briefTitle":553,"status":100,"phases":2142,"primaryCompletion":543,"completion":555,"start":556,"enrollment":546,"conditions":2143,"interventions":2144},[72],[548],[559,529],{"trials":2146,"activeCount":80},[],{"trials":2148,"activeCount":80},[],{"intervention":2150,"totalTrials":109,"cells":2151},"Evogliptin",{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2153,"activeCount":80},[],{"trials":2155,"activeCount":80},[],{"trials":2157,"activeCount":80},[2158],{"nctId":2159,"briefTitle":2160,"status":100,"phases":2161,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":2164,"conditions":2165,"interventions":2166},"NCT02689362","Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)",[71],"2018-08-09","2017-08-08",146,[1842],[2150,2167],"Sitagliptin",{"trials":2169,"activeCount":80},[],{"trials":2171,"activeCount":80},[],{"trials":2173,"activeCount":80},[],{"intervention":2167,"totalTrials":109,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":80},[],{"trials":2179,"activeCount":80},[],{"trials":2181,"activeCount":80},[2182],{"nctId":2159,"briefTitle":2160,"status":100,"phases":2183,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":2164,"conditions":2184,"interventions":2185},[71],[1842],[2150,2167],{"trials":2187,"activeCount":80},[],{"trials":2189,"activeCount":80},[],{"trials":2191,"activeCount":80},[],{"intervention":2193,"totalTrials":109,"cells":2194},"Pegfilgrastim",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2210,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2196,"activeCount":80},[],{"trials":2198,"activeCount":80},[2199],{"nctId":2200,"briefTitle":2201,"status":100,"phases":2202,"primaryCompletion":2203,"completion":2204,"start":2205,"enrollment":1902,"conditions":2206,"interventions":2209},"NCT02589301","Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations",[70],"2016-03","2016-11","2015-11",[2207,2208],"Neutropenia","Healthy",[2193],{"trials":2211,"activeCount":80},[],{"trials":2213,"activeCount":80},[],{"trials":2215,"activeCount":80},[],{"trials":2217,"activeCount":80},[]]